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Abstract
Background: Dengue fever is a virus infection that is spread by the Aedes aegypti mosquito and can cause severe disease
especially in children. Dengue fever is a major problem in tropical and sub-tropical regions of the world.
Methodology/Principal Findings: We invited dengue experts from around the world to attend meetings to discuss dengue
surveillance. We reviewed literature, heard detailed reports on surveillance programs, and shared expert opinions.
Results: Presentations by 22 countries were heard during the 2.5 day meetings. We describe the best methods of
surveillance in general, the stakeholders in dengue surveillance, and the steps from mosquito bite to reporting of a dengue
case to explore how best to carry out dengue surveillance. We also provide details and a comparison of the dengue
surveillance programs by the presenting countries.
Conclusions/Significance: The experts provided recommendations for achieving the best possible data from dengue
surveillance accepting the realities of the real world (e.g., limited funding and staff). Their recommendations included: (1)
Every dengue endemic country should make reporting of dengue cases to the government mandatory; (2) electronic
reporting systems should be developed and used; (3) at minimum dengue surveillance data should include incidence,
hospitalization rates, deaths by age group; (4) additional studies should be completed to check the sensitivity of the system;
(5) laboratories should share expertise and data; (6) tests that identify dengue virus should be used in patients with fever for
four days or less and antibody tests should be used after day 4 to diagnose dengue; and (7) early detection and prediction
of dengue outbreaks should be goals for national surveillance systems.
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Introduction
Dengue virus, which is most commonly transmitted by the Aedes
aegypti mosquito, is the most important mosquito-borne viral
disease affecting humans [1]. Caused by one of four serotypes,
dengue fever (DF) produces a spectrum of clinical illness that
ranges from an influenza-like illness to a fatal shock syndrome
(DSS). Most patients that progress to shock first develop a more
severe form of infection called dengue hemorrhagic fever (DHF).
We estimate that 3.6 billion people in 124 countries are at-risk for
infection and 500 million people infected each year [2]. Over two
million cases of DHF occur annually, and approximately 21,000
deaths are likely attributable to dengue [2].
Dengue prevention is limited vector control and treatment is
limited to supportive care to avoid shock. To address the need for
dengue prevention, several dengue vaccines are in development.
One candidate entered expanded phase 2 clinical trials in 2009
[3].
Decision making prior to vaccine introduction and monitor-
ing for effectiveness and safety after introduction require ade-
quate country specific disease surveillance data [4]. To assess
the status of dengue surveillance and to develop recommenda-
tion to improve surveillance data quality, two Dengue Preven-
tion Boards convened to discuss dengue surveillance in repre-
sentative countries. This report describes the results of that
work.
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Prevention Boards
As part of its program to facilitate the development and
introduction of a dengue vaccine in endemic countries, Pediatric
Dengue Vaccine Initiative (PDVI) [5] has sponsored two Boards
consisting of dengue experts primarily from endemic countries, the
Asia-Pacific Dengue Prevention Board (APDPB) and the Americas
Dengue Prevention Board (AmDPB) [6]. These experts are in-country
advocates for improved dengue prevention and control activities, most
working in anticipation of dengue vaccines. The Boards meet
regularly to assess various aspects of dengue prevention and control.
Meetings on surveillance
Accurate burden of disease data will be needed for informed
decision making regarding vaccine introduction [7]; however, often
the only data available are from national surveillance. For this and
other reasons, the Boards along with PDVI selected surveillance for
their first topic to address. The format for their work was two
working meetings of Board members and invited consultants and
representatives from the Ministries of Health or other agencies
involved in dengue surveillance. The objectives of the meetings were
to assess the state of dengue surveillance in selected countries and
reach a consensus on best practices. The Asia-Pacific Board met on
June 19–21, 2007; the Americas Board, on January 17–19, 2008. In
addition to Board members, meeting attendees included national
and international experts in surveillance and dengue, representatives
of ministries of health, WHO and regional offices (e.g. SEARO),
PAHO and the Caribbean Epidemiology Center (CAREC). Oral
presentations, facilitated discussions, and a survey of presenters were
used to determine the key issues and best practices.
In total, there were presentations on the surveillance programs
from twenty two countries given by representatives of Ministry of
Health or other agency participating in dengue surveillance in-
country (e.g. Institute Pasteur) (for APDPB: Australia, Cambodia,
French Polynesia, India, Malaysia, the Philippines, Sri Lanka,
Singapore, Thailand, Japan, Vietnam; for AmDPB: Argentina,
Brazil, Costa Rico, Colombia, Cuba, Honduras, Mexico, Puerto
Rico, Nicaragua, United States (South-west border states), and
Venezuela) (Figure 1). Because ensuring adequate surveillance
requires participation from several disciplines, experts presented
on topics of surveillance, epidemiology, entomology, and virology.
Each country provided a detailed description of their national
dengue surveillance system and results (Table 1 & 2). Attendees
then synthesized the comments and opinions of the Board
members. Full reports of each meeting are be available on the
website of the Prevention Boards [6].
Results
Observations on surveillance systems
The core functions of a comprehensive surveillance system are
detection, reporting, investigation, confirmation, analysis, interpreta-
tion, and response. Cooperation is essential between the healthcare
system and the public health authority because for rapid response to
emerging public health threats the public health authority is dependent
on healthcare system to generate timely and accurate case reports.
Observations on diagnosis and case definitions of
dengue
At the time of the meeting, WHO had published guidelines on
the diagnosis of dengue including case definitions; but these
guidelines were published more than 10 years ago [8]—in 2009
WHO published new guidelines with major changes in dengue case
classifications [9]. Regional offices have also drafted guidelines [10–
12]. The guidelines agree on major issues with minor variations (for
example, some include leukopenia or hepatomegaly in the case
definitions, but not all include a ‘‘suspected case’’ category).
One major difficulty with all previous guidelines is case
classification [13]. Because case fatality rates are much higher among
patients with DHF, correct classification is important for triage,
treatment, and prognosis.Obtaining a platelet count, hematocrit, and
radiographicimagingis often not possible, tootimeconsuming, or too
expensive in many healthcarefacilities in endemic countries—but the
results of these tests are required diagnostic criteria for DHF. There
was wide recognition of the need for a simplified classification system
that is still helpful for case management [13,14].
Although meeting attendees reported using similar dengue case
definition systems, surveillance methods varied between countries.
Laboratory methods also vary as well as the testing algorithms and
the interpretation of positives. For example, in Brazil and
Figure 1. Countries with local dengue transmission in the last
25 years [2].
doi:10.1371/journal.pntd.0000890.g001
Author Summary
The Pediatric Dengue Vaccine Initiative organized Dengue
Prevention Boards in the Asia-Pacific and the Americas
regions consisting of dengue experts from endemic
countries. Both Boards convened meetings to review
issues in surveillance. Through presentations, facilitated
discussions, and surveys, the Boards identified best
practices in dengue surveillance including: (1) Dengue
should be a notifiable disease in endemic countries; (2)
World Health Organization regional case definitions should
be consistently applied; (3) electronic reporting systems
should be developed and used broadly to speed delivery
of data to stakeholders; (4) minimum reporting should
include incidence rates of dengue fever, dengue hemor-
rhagic fever, dengue shock syndrome, and dengue deaths,
and hospitalization and mortality rates should be reported
by age group; (5) periodic additional studies (e.g., capture/
recapture) should be conducted to assess under-detection,
under-reporting, and the quality of surveillance; (6)
laboratory methods and protocols should be standardized;
(7) national authorities should encourage laboratories to
develop networks to share expertise and data; and (8) RT-
PCR and virus isolation (and possibly detection of the NS1
protein) are the recommended methods for confirmation
of an acute dengue infection, but are recommended
only for the four days after onset of fever—after day 4,
IgM-capture enzyme-linked immunosorbent assay is
recommended.
Surveillance Best Practices
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ambulatory and hospitalized patients, however, in Thailand and
Vietnam the majority of reported cases are hospitalized. In only
12/22 (55%) of countries represented at the meeting confirmed all
officially reported cases with laboratory testing. Nearly every
country includes suspected dengue cases regardless of age, but in
Cambodia surveillance is conducted only among children less than
15 years of age. In Singapore and Brazil, monitoring vector indices
is an integral part of the dengue surveillance system, while in
Puerto Rico it is not. The attendees reported that these differences
were not currently a problem for country level analyses but make
inter-country, regional, and global analyses and comparisons
difficult. Moreover, some difference (e.g. lack of dengue surveil-
lance among adults in Cambodia) could be an impediment to
strategic planning and implementation of a dengue vaccine since
the disease also affects adults as well as children. Moreover, the
vaccination of children is likely to also have an impact on adult
disease burden [15,16], further improving the cost-effectiveness.
Since surveillance data are needed for health ministries to target
control responses when outbreaks are detected, data must be
collected in a timely fashion. In order to better understand the
overall process, attendees reviewed the steps from infection to
reporting (Figure 2). The incubation period is, on average, one
week following the bite of an infectious mosquito. Several more
days pass before symptoms become severe enough to cause the
patient to seek medical attention, and still more time is required
for the symptoms of DHF to develop. Outpatient clinic-based
surveillance will detect cases earlier than inpatient facilities,
potentially allowing more time for public health action.
The medium for reporting ranged from paper case report
forms, to hand-held computers, to internet-based systems. A case
study from Nicaragua showed that hand-held computers, although
initially requiring significant investment in infrastructure and
training, do reduce reporting time. In Kolkata, India, special
mapping of cases has been used to target control activities. In
Singapore and Brazil, ministries are also using intranet-based data
entry software allowing staff to directly enter data on cases and Ae.
aegypti breeding sites in the field. The data are then immediately
available to plan interventions and follow-up. All countries are
dependent on paper forms for case reporting before any additional
Table 1. Characteristics of national surveillance systems.
Country
Case
Definition*
Surveillance
Method
{
Source of
Cases
{ Ages
Reporting Legally
Required
1
Vector Surveillance
Conducted
"
Queensland, Australia WPRO Passive OP, IP All Yes Yes
Cambodia WPRO Passive IP 0–15 Yes No
Sentinel IP 0–15
French Polynesia WPRO Passive OP, IP All Yes No
India SEARO Sentinel OP, IP All No Yes
Japan WPRO Passive OP, IP All No No
Malaysia WPRO Passive OP, IP All Yes Yes
Philippines WPRO Passive OP,IP All Yes No
Sentinel IP All
Singapore WPRO Passive OP, IP All Yes Yes
Sri Lanka SEARO Passive OP, IP All Yes Yes
Thailand SEARO Passive IP All Yes No
Sentinel IP All
Vietnam WPRO Passive OP, IP All Yes Yes
Sentinel OP, IP All
Argentina PAHO Passive OP, IP All Yes Yes
Brazil PAHO Passive OP, IP All Yes Yes
Colombia PAHO Passive OP, IP All Yes No
Costa Rica PAHO Passive OP, IP All Yes Yes
Cuba PAHO Active OP, IP All Yes Yes
Honduras PAHO Passive OP, IP All Yes Yes
Mexico PAHO Passive OP, IP All Yes Yes
Nicaragua PAHO Passive IP All Yes No
Puerto Rico PAHO Passive OP, IP All Yes No
United States PAHO Passive OP, IP All No No
Venezuela PAHO Passive OP, IP All Yes No
*Case definition used for dengue surveillance was same as World Health Organization Region Office recommended definition: WPRO = Western Pacific Regional Office;
SEARO = Southeast Asia Regional Office; Pan American Health Organization;
{Method of case ascertainment by national dengue surveillance system: active, passive or sentinel site surveillance;
{Source or location where cases are detected: OP = Outpatient clinics; IP = Inpatient or hospitalized;
1Reporting of dengue cases is mandated by law;
"Mosquito surveillance is included as part of the national surveillance system and is not just in response to outbreaks.
doi:10.1371/journal.pntd.0000890.t001
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the surveillance office, to be entered and analyzed, and finally be
reported. However, many countries are developing improved
methods for data collection for targeted interventions.
Another key issue is the needs of stakeholders with interests in
dengue diagnosis and surveillance. These stakeholders include the
general public, senior policy-makers, academics, and legislators. A
diverse group, their interests range from the parents of sick
children who want immediate and accurate test results—knowing
the diagnosis allows them to cope better—to healthcare workers,
staff in laboratories, public health and vector control authorities.
All want a point-of-care test to speed accurate diagnosis and
Table 2. Dengue surveillance data from countries represented at the Prevention Board Meetings.
Country Population
Total Cases
(Year)
Reported
DF:DHF
DHF Case
Fatality
Rate
Peak
Age
(years) Website for current dengue surveillance data
Asia-Pacific Region
Australia
(North
Queensland)
664,440 58 (2007)
140 (2008)
No DHF
reported
ND* 32 http://www.health.qld.gov.au/dengue
Cambodia 13,000,000 9,040 (2005)
16,649 (2006)
1.7:1 0.9% 5–10 http://www.moh.gov.kh/
French
Polynesia
132,900 3 (2005)
818 (2006)
333:1 ,0.1% 10–19 http://www.vice-presidence.gov.pf/UserFiles/Bull%20Aout%2008.
pdf
India 1,028,000,000 11,985 (2005)
9,680 (2006)
ND ND 14–45 http://www.nvbdcp.gov.in/
Japan Travelers Only 31 (2003)
49 (2004)
ND ND N/D http://www.nih.go.jp/vir1/NVL/DengueNet%20Web/egdenguejp.
htm
Malaysia 24821286 39,654 (2005)
18,240 (2006)
16:1 3.6% 20–24 http://www.moh.gov.my/pr_categories/1/press_releases
Philippines 84,241,341 33,490 (2005)
36,891 (2006)
2:3 ,1% 1–10 http://www2.doh.gov.ph/nec
Singapore 4553009 14,209 (2005)
3,100 (2006)
35:1 0.003 15–24 http://www.dengue.gov.sg/
Sri Lanka 20926315 5,965 (2005)
11,972 (2006)
3:1 0.4% 20–29 http://www.epid.gov.lk/
Thailand 62,000,000 34,291 (2005) 10:1 ,0.2% 10–15 http://epid.moph.go.th
Vietnam 83,119,916 60,982 (2005)
77,818 (2006)
ND ,0.1% ,15 http://www.wpro.who.int/health_topics/dengue/data.htm
Americas Region
Argentina 38,592,150 34 (2005)
181 (2006)
ND ND ND http://www.paho.org/english/ad/dpc/cd/dengue.htm
Brazil 189,335,187 203,789 (2005)
346,550 (2006)
551:1 11% 20–39 http://portal.saude.gov.br/SAUDE/area.cfm?id_area=920 (Boletim)
Colombia 42,090,512 39,825 (2005)
38,271 (2006)
6:1 5% ND http://www.bvs-vspcol.bvsalud.org/php/index.php (Notificacio ´n
Semanal Obligatoria)
Costa Rica 4.401.845 37,798 (2005)
12,052 (2006)
137:1 ND 10–34 http://www.ministeriodesalud.go.cr/index.php/inicio-vigilancia-
salud-boletines-ms
Cuba 11,416,987 14,8883
(2001–2002)
178:1 4% adults http://www.paho.org/english/ad/dpc/cd/dengue.htm
Honduras 7,400,000 18843 (2005)
7800 (2006)
45:1
74:1
3% $15 http://www.paho.org/english/ad/dpc/cd/dengue.htm
Mexico 108700891 29,836 (2006)
16,862 (2005)
4.8:1 0.4% 10–14 http://www.dgepi.salud.gob.mx
Nicaragua 5,142,098 13,831 (2005)
10,073 (2006)
26:1 2% 5–9 http://www.minsa.gob.ni/vigepi/html/boletin.html
Puerto Rico 3,937,316 6,039 (2005)
3,286 (2006)
84:1 6% 15–19 http://www.salud.gov.pr/Datos/VDengue/Pages/default.aspx (Spanish)
http://www.cdc.gov/ncidod/dvbid/dengue/documents/Weeklyreport.
pdf (English)
United States
{ 11,000,000 28 (2005) 16:9 0 ND http://www.cdc.gov/dengue/epidemiology/index.html#surv
Venezuela 26084662 39,860 (2006)
42,198 (2005)
9:1 0.1% 2–9 http://www.mpps.gob.ve/modules.
php?name=Downloads&cid=31
*ND = No data;
{USA-Mexico border only.
Additional websites with current dengue data: PAHO: http://www.paho.org/english/ad/dpc/cd/dengue.htm; Asian ArboNet: http://www.nih.go.jp/vir1/NVL/
DengueNet%20Web/ToppageArboNet.htm; Caribbean Epidemiology Centre: http://www.carec.org/; WHO: http://www.who.int/globalatlas/default.asp.
doi:10.1371/journal.pntd.0000890.t002
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general public, including travellers and Ministries of Health) are
more likely interested in more accurate tests to allow improved
burden of disease estimates which could effect budget allocations
for control.
In most countries diagnostic testing and surveillance relies on
healthcare practitioners and laboratory staff to report cases but
they receive little benefit. Confirmatory diagnostic tests such as
virus isolation or reverse transcriptase-polymerase chain reaction
testing (RT-PCR) require expertise and equipment usually found
only in reference laboratories. However, several attendees
explained that the time required for a sample to reach and to be
processed at centralized facilities often results in delays that render
the results useless to the treating physician. Further delays occur if
the information provide on a sample is incomplete or if batch-
testing of samples is conducted. After testing, the report generated
requires verification, approval and delivery (e.g. mailing). As a
consequence, health care providers in most countries must treat
patients empirically [17].
The attendees concluded that simplified case reporting [18],
rapid turnaround of results, and training healthcare providers in
reporting [19] can be important ways to encourage continued
reporting of cases. Mandatory reporting, they explained, rarely
guaranteed reporting.
Strengths and weaknesses of existing surveillance
systems
Strengths. Attendees were asked to identify the strengths and
weaknesses of their systems. Most indicated that their countries
had adequate infrastructure and surveillance systems, and the
adjectives ‘‘dedicated’’, ‘‘committed’’, ‘‘skilled’’, and ‘‘motivated’’
were widely used to describe the quality of the personnel engaged
in surveillance. They reported some country-specific but effective
links between the various stakeholders; especially healthcare
providers, laboratory staff, and the public health and vector
control authorities. However, many of these relationships are
dependent on personal contacts which are affected by staff
turnover.
Weaknesses. A common perception among meeting
attendees was that disease control is politically more important
than prevention. That is, highly visible outbreak response through
spraying is considered more important than outbreak prevention.
Specifically, during outbreaks, public demand for action often
leads to pesticide spraying [20–23] which is unlikely to be effective
since the pesticide released in the streets is unlikely to reach the
adult mosquitoes resting and feeding inside homes [24].
Lack of preventive services in the provinces is seen as a further
impediment to conducting adequate surveillance. Further, even
when adequate infrastructure exists, data are rarely used locally;
rather they are forwarded to the central ministry offices for official
evaluation, missing the opportunity for an immediate local
response. Diagnostic tests further complicate the situation because
the results are often difficult to interpret by the healthcare
providers and public health practitioners unfamiliar with the
limitations of the tests [25]. Lack of funding for laboratory
confirmation of cases and having those services available only at
central level were reported as further weaknesses. One participant
remarked that local pubic health agencies in large countries such
as Brazil have their response time greatly delayed if they must wait
for laboratory confirmation at the national level. Indeed, while
experts agreed that staff conducting surveillance were committed,
under-detection and under-reporting of dengue cases were
significant and often due to the design of the surveillance system
and lack of funding. Also, data sharing and full coordination of
entomologic surveillance conducted by vector control units and
human disease surveillance conducted by epidemiologists is
needed to improve detection of increased transmission sufficiently
early to prevent or control outbreaks. Finally, virological
surveillance is under-utilized or in some countries, completely
lacking: It’s importance emphasized by the fact that large
outbreaks tend to follow changes or reintroductions of serotypes.
Discussion
As an outcome of the meeting, attendees agreed on best
practices on laboratory practices, data gathering, analyses,
reporting, and feedback for dengue surveillance.
Guiding principles
Every dengue endemic country should systematically gather
data in an established dengue surveillance system [12], and each
system should have a quality assurance mechanism. Legislation
should make dengue a notifiable disease in every affected country
[12] to improve the capture of cases by surveillance. However,
even mandatory reporting is not sufficient; additional efforts are
needed to improve and maintain a high level of quality reporting.
All suspected cases must be reported to a central dengue unit in
the health ministry as rapidly as possible and providers should be
reminded that timely reporting can lead to effective response [26].
Laboratory confirmation of suspected cases should always be
sought, except during outbreaks. Once an outbreak is confirmed
no added information is gained by testing all samples; a subset of
the samples is usually sufficient to track the outbreak [17]. That
said, health providers should be informed that not all samples
submitted during outbreaks will necessarily be tested. In outbreaks,
data collection and analysis should be completed as rapidly as
possible.
Reporting should be encouraged from all levels of healthcare
facilities in both the public and the private sectors [12]. In
particular, mechanisms to involve the private sector should be
developed; one possible way to encourage reporting is a rapid turn
around of dengue diagnostic test results which can be provided
free of charge[12]. While the turn around may not be quick
enough to affect patient care, rapid return of results to submitting
Figure 2. Timeline showing transmission cycle, clinical disease,
and surveillance events. After the first infection results in clinical
disease several additional infections occur before a public health
response occurs in response to the index case.
doi:10.1371/journal.pntd.0000890.g002
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acumen. Reporting should be expanded to also include cases
presenting to outpatient facilities, but staff in such settings may
need further training to ensure the quality of data. To confirm and
understand the burden of disease, periodic additional studies (e.g.
using capture-recapture methods) should be conducted and
incorporated into the system when possible. This will also
determine the representativeness of the surveillance data.
Laboratory practices
Laboratory confirmation improves the specificity of surveillance
[27], but laboratory methods and protocols should be standard-
ized. This can be achieved through national and international
networking of dengue laboratories to share expertise, protocols
and data.
A critical element for the successful laboratory diagnosis of an
acute dengue infection is the timely collection of high quality
samples. Monitoring the time from case identification to receipt of
blood samples in the testing facility may assist in maintaining high
quality specimens.
RT-PCR and virus isolation are the two recommended methods
for virus identification. Monitoring serotypes and sequencing
isolates can provide useful markers for outbreak prediction [28].
Detection of the non-structural protein antigen NS1 may also be
useful, but it must undergoing further evaluation [17]. For
serologic testing, the hemagglutination-inhibition assay remains
the gold standard of serological assays and should be maintained
in those laboratories capable of performing it; however, enzyme-
linked immunosorbent assays for IgM and IgG are considered the
minimum requirement for confirmation of cases [29].
Testing schedules. In the first four days after onset of fever,
either RT-PCR or virus isolation are the recommended assays for
confirmation of dengue infection [30]. IgM antibody detection is
an alternative if virus detection or isolation is negative, but may
not be detectable in the early stages of the illness [31]. After day 4,
serology is the method of choice [27]. Paired blood samples
collected on days 0–4 of illness and days 10–21 of illness are
necessary for definitive serological diagnosis by IgM
seroconversion. Where possible, IgG antibody detection should
also be performed, particularly on suspected secondary dengue
infections due to the absence of IgM antibody in up to 30% of
those cases [32]. A four-fold increase in titer of IgG is also
consistent with a recent dengue infection, but IgG antibodies are
not dengue-specific and may have been caused by flaviviruses
other than dengue [31].
Quality assurance and control. Support should be
provided for quality control, proficiency testing and good
laboratory practice at the WHO reference laboratory level, the
national level and the local level [17]. Every assay should include
standards (i.e. positive, negative and cut-offs). Experience and
methodologies should be shared. Financial support for reagent
production and distribution to national laboratories would reduce
some variability in results and reduce cost. In the past, several
WHO reference laboratories provided reagents free of charge on
request to national laboratories. This improved comparability of
results but was not financially sustainable.
Reporting
At least weekly reporting of aggregate results was considered by
the attendees as the minimum standard during peak transmission.
To conserve resources, reporting could be reduced to biweekly
during periods of low transmission. During an outbreak, more
frequent reporting, perhaps on a daily basis, would be useful.
However, it is important to note that reporting would be affected
by the operating hours of the reporting facilities (e.g. facilities
closed on weekends or holidays could artificially reduce reported
cases and create surveillance artifacts). Reports should reach the
surveillance units within 48 hours of form completion.
Especially since dengue occurs frequently in young adults in
Southeast Asia, it is recommended that the usual categories for
reporting in health information systems should be used, namely
less than 1 year, 1–4 years, 5–14 years and older than 15 years.
However, reporting the median age of cases across all ages is also a
useful statistic to track, and may be more useful for comparison if
countries are using different age categories. Moreover, if the
median age is reported by countries not including cases of all ages
because the peak incidence is in children, the overall age
distribution could be modeled with the available data. Electronic
reporting systems should be developed and used broadly and such
applications would facilitate formal reporting among countries.
Analysis and feedback
Meeting attendees emphasized the need to determine the
incidence of severe cases through measurement of incidence rates
of dengue fever, dengue hemorrhagic fever, and dengue shock
syndrome, with hospitalization rates and mortality rates broken
down by age group consistently applying the WHO regional case
definitions. Weekly incidence of dengue, with data stratified by
age, gender, and location should also be rapidly reported to allow
effective use of vector control resources and to monitor
intervention programs. In addition analyses should be conducted
to detect and forecast dengue outbreaks through determination of
the national threshold for outbreak alert and response [33], to
monitor the seasonality, age distribution, and transmission
patterns and to evaluate and guide the introduction of potential
dengue vaccines. Vector surveillance requires baseline data for
comparisons. When relevant data are available, analyses should be
conducted to identify locations and patterns of the vector
population (species, density, and vector-control indices) and should
also be used to monitor interventions (with disease reduction as a
measure of impact, and house index, container index, and Breteau
index as indicators of outcome).
In conclusion, the two Dengue Prevention Boards met to discuss
the practice and logistics of dengue surveillance. The attendees
applied their practical experience and discussed the strengths and
weakness for the countries represented at the meeting. They then
suggested best practices in dengue surveillance in endemic
countries. For PDVI, improved surveillance serves many purposes
including generating more accurate estimates of disease burden,
further demonstrating the need for a dengue vaccine, supporting
clinical evaluations of candidate dengue vaccines and providing
more robust surveillance for monitoring the impact of the eventual
introduction of dengue vaccines in national immunization
programs.
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